{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-048316","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.301068+00:00","generated_at":"2026-05-29T11:26:30.630254+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Serina Therapeutics secures $10M equity financing from Juvenescence at $10/share (120% premium)","bullets":["Financing of 1M shares at $10/share, a 120% premium to Nov 26 closing price.","First $5M tranche received Nov 27, 2024; second $5M due by Jan 31, 2025.","Proceeds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025.","Juvenescence surrendered 755,728 post-merger warrants; received replacement incentive warrants exercisable at $18.","Special committee of independent directors approved the related-party transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-048316","json":"https://secwatch.observer/filing/0001493152-24-048316.json","markdown":"https://secwatch.observer/filing/0001493152-24-048316.md","text":"https://secwatch.observer/filing/0001493152-24-048316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224048316/0001493152-24-048316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224048316/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:26:30.630254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}